CURRICULUM VITAE — KATHLEEN TOUPS, M.D., CCTI

BUSINESS ADDRESS

PLACE OF BIRTH
New Orleans, Louisiana

CURRENT POSITIONS
Executive and Medical Director- 1997 to Present           
Bay Area Research Institute                                    
Lafayette, California                                                

EDUCATION
University of California, Davis
Davis, California
Bachelor of Science, with Honors, Anthropology
1980-82

POSTGRADUATE EDUCATION
University of California, Davis
Davis, California
Department of Genetics - Graduate Division
Graduate Fellowship Recipient
1982-1983

MEDICAL EDUCATION
Louisiana State University Medical School
New Orleans, Louisiana
Doctor of Medicine
May, 1987

POSTDOCTORAL TRAINING
Mercy Hospital and Medical Center
San Diego, California
Transitional Internship
1987-1988

University of California, San Diego
La Jolla, California
Psychiatry Residency
1989-1992

CERTIFICATION

• Federal Licensure Examination (FLEX), l987
• American Board of Psychiatry and Neurology - Diplomate, 1994
• Added Qualifications in Geriatric Psychiatry - Diplomate, 1995
• Certified Clinical Research Investigator (ACRP) - 2003

LICENSURE
California A045048, l988

HOSPITAL AFFILIATIONS
Mt. Diablo Medical Pavilion – Courtesy                       
Concord, California                                                           

ACADEMIC POSITION
Assistant Professor of Clinical Psychiatry, University of California, Davis, CA, 1994 - 1996

OTHER APPOINTMENTS

• AstraZeneca Advisory Board – 1998 - 2001
• Expert Consultant – Forest Laboratories and Parke-Davis Pharmaceuticals
• Lilly Atomoxetine Advisory Board – 2001 - 2003
• National Alliance for the Advancement of ADHD Care (NAAAC) - Board of Directors – 2002 - 2004
• Shire ADHD Advisory Board – 2004
• Expert Consultant – MDS Pharma Services – 2006

HONORS

• Phi Kappa Phi National Honor Society, 1982
• Departmental Citation in Anthropology, University of California, Davis, 1982
• Aesculapian Honor Society, 1983-1987
• American Association for Geriatric Psychiatry Mead-Johnson Fellowship, 1991-1993

CLINICAL, ADMINISTRATIVE AND ACADEMIC POSITIONS

Research Assistant in Human Genetics, 1981-1982
University of California, Davis
Davis, California

Archaeologist in the California Great Basin, summer 1982
University of California, Davis
Davis, California

Teaching Assistant in Physical Anthropology, 1982-1983
University of California, Davis
Davis, California

General Practitioner in Family Medicine, 1988-1989
San Ysidro Community Health Center
San Ysidro, California

Urgent Care Physician, 1988-1991
Readicare Medical Group
San Diego, California

Private Practice, Psychiatry, 1991-1993
Affiliated Mental Health Professionals
San Diego, California

Psychiatry ER Physician, Consult-Liaison Psychiatry, and O/P Psychiatry, 1993
Merrithew Memorial Hospital and Pittsburgh Community Clinic
Contra Costa County Mental Health
Martinez and Pittsburgh, California

Staff Psychiatrist, 1993-1994
Kaiser Permanente Medical Center
Department of Mental Health
Walnut Creek, California

VA Chief of Inpatient Psychiatry, 1994-1996
Residency Training Site Director
David Grant Medical Center
Travis Air Force Base, California

Assistant Professor of Clinical Psychiatry, 1994-1996
University of California, Davis
Davis, California

Private Practice - Adult and Geriatric Psychiatry, 1996-1997
Antioch, California

Intensive Outpatient Psychiatry Program and Consultant to Home Health Nursing, 1997-1998
Kaiser Permanente Medical Center
Walnut Creek and Martinez, California

ACADEMIC ACTIVITIES

UC Davis Residency Training Site Director
David Grant Medical Center, 1994-1996

Chair: Junior Faculty Group, Department of Psychiatry
UC Davis Medical School, 1995-1996

Faculty Advisor: Third Year Medical Students
UC Davis Medical School, 1995-1996

Lecturer and Discussion Group Leader: Introduction to Psychopathology
UC Davis Medical School, Spring, 1995 and 1996

Discussion Group Leader: Human Sexuality
UC Davis Medical School, 1996

Organizer and Instructor: Weekly Special Topics Seminar for Psychiatry Residents
David Grant Medical Center, 1994-1996

Organizer and Coordinator: Psychiatry Grand Rounds
David Grant Medical Center, 1994-1996

Member: Training Advisory Group
UC Davis Department of Psychiatry, 1994-1996

PROFESSIONAL ACTIVITIES

Delegate to the Medical Student Section of the AMA, 1985-1987

Developed Impaired Medical Student Program at LSU (Phoenix Society), 1985

Council Member of Phoenix Society, 1985-1987

American Medical Student Association (AMSA)

• Trustee, Region VII, AMSA National Board, 1986-1987
• AMSA Representative to the American Psychiatric Association Internal Steering Committee on Alcohol and Other Drug Abuse Project, 1986-1987
• Chairperson, Reference Committee on Corporatization of Health Care - AMSA National Convention, 1986
• Louisiana State Delegation Leader - AMSA National Convention (Coordinated Congressional lobbying efforts), 1986
• Panelist on Impaired Medical Student Programs - AMSA National Convention, 1986
• Co-Chairperson, AMSA Chemical Dependency Project - Advisory Board, 1985-1986
• President, LSU Chapter AMSA, 1984-1985
• Secretary, LSU Chapter AMSA, 1983-1984
• Member, Legislative Affairs Task Force, 1983-1987

COMMITTEES

Member - Louisiana State Medical Society Mental Health Task Force, 1986-1987
Member - Mercy Hospital and Medical Center: House Staff Committee Liaison Coordinator, 1987-1988

Member - San Ysidro Health Center: Quality Assurance Committee, 1988-1989: Medical Forms Committee, 1988-1989
Member - San Diego Society of Psychiatric Physicians: Mental Health Services Committee (Access to Health Care), 1988-1989

Member - UCSD Department of Psychiatry: Graduate Education Committee, 1989-1990
Member - American Association for Geropsychiatry: Private Practice and Medicare Committee, 1991-1993

Member - American Association for Geropsychiatry: Board of Directors (Resident Representative), 1991-1993
Member - Pittsburgh Community Clinic: Quality Assurance Committee, 1993

Member - Kaiser Permanente: Biological Psychiatry Committee, 1994
Chair      - Kaiser Permanente: Department of Psychiatry Medical Education, 1994

Member - VA: Clozaril Committee, 1994-1996
Member - VA: Quality Assurance Committee, 1994-1996
Member - VA: David Grant Medical Center Operations Committee, 1995-1996
Member - VA/Air Force: Mental Health Flight Committee, 1995-1996

Member - VA/Air Force: Executive Committee, 1995-1996
Member - VA: Pharmacy and Therapeutics Committee, 1996

Secretary - Board of Directors, Northern CA Psychiatric Society, 2006-Present

PROFESSIONAL SOCIETIES

• American Psychiatric Association
• California Psychiatric Association
• Northern California Psychiatric Association
• East County Geriatric Medicine Journal Club
• Contra Costa County Organization of Women Psychiatrists

GOOD CLINICAL PRACTICE TRAINING

2005 — Investigator Training for Medical Research
Western Institutional Review Board (WIRB)
February 3, 2005

2004 — Good Clinical Practices (GCP) and DNA Sampling
ePharmaLearning
November 11, 2004

2004 — NIH Clinical Research Training Course
February 19, 2004

2003 — Informed Consent Training
Coast IRB
January 31, 2003

2001 — Investigator Support Initiative Training in Good Clinical Practices
Pharmacia
March 19-21, 2001
Scottsdale, AZ

RESEARCH

2007 — Primary Investigator
Sanofi-EFC5582 (GAD)
An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating the Efficacy, Safety and Tolerability of Two Fixed Doses (100 mg and 30 mg Once Daily) of Saredutant in Patients with Generalized Anxiety Disorder.

2007 — Primary Investigator
Sanofi-EFC6607 (Depression)
A multi-cetner, double-blind, parallel groups, fixed dose, 4-arm, placebo and paroxetine controlled 8-week efficacy study of 2 oral doses of SR58611A (175mg or 350mg, b.i.d.) in adult outpatients with Major Depressive Disorder.

2007 — Primary Investigator
Sanofi-EFC5582 (GAD)
An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating the Efficacy, Safety and Tolerability of Two Fixed Doses (100 mg and 30 mg Once Daily) of Saredutant in Patients with Generalized Anxiety Disorder.

2007 — Primary Investigator
Abbott - M06-889
The Long-Term Safety and Tolerability of ABT-089 in Adults with Attention Deficit-Hyperactivity Disorder (ADHD):  An Open-Label Extension Study for M06-855

2007 — Primary Investigator
Abbott - M06-855
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults with Attention Deficit-Hyperactivity Disorder (ADHD).

2007 — Primary Investigator
Novartis - A2301E (MDD)
Treatment of Major Depressive Disorder (MDD), a 52-week, open-label extension for A2301.

2007 — Primary Investigator
Novartis - A2301(MDD)
An 8-week, randomized, double-blind, fixed-dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension.

2007 — Primary Investigator
New River - NRP104.304
A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults with Attention Deficit Hyperactivity Disorder (ADHD).  Extension for NRP104.303

2007 — Primary Investigator
Myriad(ext)MPC-7869-04-005
Open-Label Protocol MPC-7869-05-009.001:  Open Label STudy of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer's Type.

2006 — Primary Investigator
New River – NRP104.303
A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD).

2006 — Primary Investigator
Cephalon - 2027
A 9-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil (255, 340, 425, and 510 mg/day) as Treatment for Adults With Attention-Deficit/Hyperactivity Disorder

2005 — Primary Investigator
New River – NRP104.303
A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD).

2005 — Primary Investigator
Cephalon-CEP10953
A 12-Month, Open-Label, Flexeble-Dosage (100 to 250 mg/day) Study of the Safety of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With and Open-Ended Extension Period).

2005 — Primary Investigator
Voyager-VP-AD-301
A Double-Blind Placebo-Controlled Study of VP4896 for the Treatment of Mild-to-Moderate Alzheimer's Disease.

2005 — Primary Investigator
Voyager-VP-AD-104E
Open Label Extension of a Double-Blind Placebo-Controlled Study of Leuprolide Acetate Depot in the Treatment of Alzheimer's Disease in Men.

2005 — Primary Investigator
Eisai, Inc. – E2020-A001-412
A One Year Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Subjects with Mild Cognitive Impairment..

2005 — Primary Investigator
Cortex – CX717-051
A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy and Safety of the Ampakine Compound, CX717, Versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder

2005 — Primary Investigator
Shire SPD465.304
A Phase III, Multi-Center, Open-Label Safety Study to Evaluate the Safety and Efficacy of SPD465 in Adults with ADHD for a 12-Month Period.

2005 — Primary Investigator
Shire SPD465.303
A Phase III, Randomized, Double-blind, Multi-Center, Placebo-controlled, Parellel-group, Forced Dose Tiration, Safety and Efficacy Study of SPD 465 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD).

2005 — Primary Investigator
Medicinova-MN-305-CL-001
A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Flexible Dosing Regimens of MN-305 in Patients with DSM-IV Defined Generalized Anxiety Disorder (GAD).

2005 — Primary Investigator
Shire SPD485.303
A Phase III, Multi-center, Open-label Study of Methylphenidate Transdermal System (MTS) in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD).

2005 — Primary Investigator
Merck-0928(014-00)
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Efficacy and Safety Extension Study of MK-0928 15 mg and 10 mg in the Treatment of Adult Outpatients With Primary Insomnia

2005 — Primary Investigator
Myriad - MPC-7869-04-005
Phase III Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type.

2005 — Primary Investigator
Saegis - SGS742-CL03
A Double-Blind, Double Dummy, Placebo Controlled, Two-Period Crossover Study in Adults with Attention Deficit Hyperactivity Disorder (ADHD).

2004 — Primary Investigator
Shire - SPD465.301
A PhaseIII, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention Deficit Hyperacitivity Disorder (ADHD).

2004-05 — Primary Investigator
Johnson & Johnson - R096769-PRE-3002
A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and as needed Dosing With Dapoxetine in the Treatment of Premature Ejaculation.

2004-05 — Primary Investigator
Sention – C105 22020
A randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, and efficacy with mild cognitive impairment (MCI).

2004-05 — Primary Investigator
GSK - 100368
A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/day) and Extended-release venlafaxine (Effexor XR, 75-225 mg/day) in Subjects with Major Depressive Disorder.

2004 — Primary Investigator
Shire SPD485.302
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-group, Placebo-controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. Concerta in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD).

2004 — Primary Investigator
Lilly B4Z-US-LYCU
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults with ADHD Over an Extended period of Time: With a Brief Evaluation of Executive Cognition.

2004 — Primary Investigator
Voyager-VP-AD-104
A Double-Blind Placebo-Controlled Study of Leuprolide Acetate Depot in the Treatment of Alzheimer's Disease in Men.

2004 — Primary Investigator
Shire – SLI381-312
Open-Label, Multi-Center Study to Assess Safety, Tolerability, and Effectiveness Associated with the use of ADDERALL XR in Adults with Attention Deficit Hyperactivity Disorder and Evaluate an ADHD-specific Novel Quality of Life Measure.

2004-05 — Primary Investigator
Cephalon, Inc. - CEP10953
A 12-Month, Open-Label, Flexeble-Dosage (100 to 250 mg/day) Study of the Safety of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With and Open-Ended Extension Period).

2003 — Primary Investigator
Abbott Laboratories – M03-594
A Randomized, Double-Blind, Placebo-Controlled, 4-Period Crossover Pilot Study of the Safety of the Safety and Efficacy of Multiple Doses of ABT-089 in Adults with Attention Deficit-Hyperactivity Disorder (ADHD).

2003 — Primary Investigator
Shire Pharmaceutical Development Inc. – SLI381.315
A Phase III, Randomized, Multi-Center, 18-month, Open-label Safety, Tolerability and Efficacy Study of ADDERALL XR in the Treatment of Adolescents aged 13-18 with Attention Deficit Hyperactivity Disorder (ADHD).

2003-04 — Primary Investigator
Shire Pharmaceutical Development Inc. – SPD473.203
A Phase II, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD473 in Adults Aged 18-55 with Attention Deficit Hyperactivity Disorder (ADHD).

2003-04 — Primary Investigator
Alza Corporation – C2002-014
An Open Label Study of the Long-term Safety of Dapoxetine HCI in the Treatment of Rapid Ejaculation.

2003-04 — Primary Investigator
Alza Corporation – C2002-013
A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Efficacy and Safety of Dapoxetine HCI in the Treatment of Rapid Ejaculation.

2003-04 — Primary Investigator
Shire Pharmaceutical Development Inc. – SLI381.314
A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of ADDERALL XR with an Open-label Extension, in the Treatment of Adolescents aged 13-17 with Attention Deficit Hyperactivity Disorder (ADHD).

2003-04 — Primary Investigator
Takeda Pharmaceuticals – 01-02-TL-375-022
A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects with Chronic Insomnia.

2003-04 — Primary Investigator
Novartis Pharmaceuticals Corporation - E2302
A 5-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group, fixed-dosed study of the efficacy and safety of Focalin™ LA (dexmethylphenidate hydrochloride) administered once daily in adults with Attention-Deficit/Hyperactivity Disorder

2003-04 — Primary Investigator
Ortho McNeil-CAPSS-169
The Effect of Ortho Tri-Cyclen on Bone Mineral Density in Pediatric Subjects with Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study

2002-03 — Primary Investigator
GlaxoSmithKline AK130934
An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/day to Assess the Efficacy, Safety and Effects on Health Outcomes in the Treatment of Adults with Attention-Deficit Hyperactivity Disorder.

2002-03 — Primary Investigator
Lilly B4Z-MC-LYBM
A Double-Blind Study of Treatment Optimization with Atomoxetine Hydrochloride in Adults with DSM-IV Attention Deficit/Hyperactivity Disorder

2002-05 — Primary Investigator
Somerset S9303-P0204
A Phase III, Open Label Study of the Safety, Tolerability, and Efficacy of the Selegiline Transdermal System in Elderly Subjects with Major Depression

2002 — Primary Investigator
Shire 381.303
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of ADDERALL XR™ in Adults with Attention Deficit Hyperactivity Disorder.

2002-04 — Primary Investigator
Shire 381.304
A 12-Month, Open-Label Study of ADDERALL XR™ in Adults with Attention Deficit Hyperactivity Disorder.

2001-02 — Primary Investigator
GlaxoSmithKline SB-659746-A002
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Efficacy and Safety of Three Doses of SB-659746-A (5mg, 10 mg and 20 mg) Versus Placebo in Patients with Major Depressive Disorder.

2001-03 — Primary Investigator
Merck – MK-0869
A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of MK-0869 in the Treatment of Patients With Major Depressive Disorder.

2001-02 — Primary Investigator
Lilly F1D-US-HGJU
A Controlled Trial of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenic and Schizoaffective Subjects with Comorbid Depression.

2001 — Primary Investigator
B4Z-MC-LYAI
A Long-Term, Open-Label, Safety Study of Tomoxetine Hydrochloride in Patients, 6 years and older.

2001-02 — Primary Investigator
B4Z-MC-LYAQ
Safety and Efficacy of Atomoxetine or Atomoxetine Plus Fluoxetine in the Treatment of Mixed Attentional and Affective Disorders.

2001-02 — Primary Investigator
Pfizer A1481074
A parallel Group, Multicenter flexible dose study with a double blind, randomized, placebo-controlled phase and an open-label phase to evaluate the efficacy and safety of Viagra (Sildenafil Citrate) in males with Serotonergic Antidepressant associated Erectile Dysfunction.

2000-01 — Primary Investigator
AstraZeneca 5077IL/0041
A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Sustained-release Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the treatment of Patients with Schizophrenia.

2000-01 — Primary Investigator
AstraZeneca 5077IL/0099
A Placebo-Controlled Trial of the Safety and Efficacy of SEROQUEL as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania.

2000-04 — Primary Investigator
B4Z-MC-LYAR
A Long-Term Open-Label Safety Study of Tomoxetine Hydrochloride In Adult Outpatients with DSM-IV Attention Deficit/Hyperactivity Disorder.

2000 — Primary Investigator
Parke-Davis 1088-090-025
A Placebo-Controlled Study of Pregabalin in Elderly Patients With Generalized Anxiety Disorder. 

Primary Investigator
Pharmacia & Upjohn M/2020/0047
Reboxetine, Placebo, and Paroxetine Comparison in Patients with Major Depressive Disorder

2000-01 — Primary Investigator
Lilly B47-MC-LYAO
A phase III randomized, double-blind comparison of placebo and tomoxetine in adult outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder.

2000-02 — Primary Investigator
Lilly B47-MC-LYAB
A phase III open label, long-term, safety and efficacy study of tomoxetine hydrochloride in outpatients with ADHD, ages 6 to 18 years.

2000-01 — Primary Investigator
Pfizer 0501015
A 24-week, open-label extension study of Zoloft in children & adolescent outpatients previously diagnosed with Major-Depressive Disorder.

2000 — Subinvestigator
Shire-381.301
A randomized, double-blind, placebo-controlled, parallel-group study of SL1381 in children with Attention Deficit Hyperactivity Disorders.

2000 — Subinvestigator
Shire-381.302
A 12-month, open-label study of SL1381 in children with Attention Deficit Hyperactivity Disorder.

2000 — Subinvestigator
Alza C-99-018
Open-label study to evaluate participants use and safety of OROS (methylphenidate HCI) in participants with ADHD in a community setting.

2000-2003 — Primary Investigator
Bristol-Myers Squibb CN138-005
A multicenter, randomized, double-blind, placebo controlled flexible-dose study of Aripiprazole in the treatment of institutionalized patients with psychosis associated with dementia of the Alzheimer’s type.

2000-01 — Primary Investigator
Bristol-Myers Squibb CN 138-007
A randomized, double-blind, placebo-controlled , flexible –dose study of two fixed doses of aripiprazole in the treatment of patients with Acute Mania.

2000-01 — Primary Investigator
Bristol-Myers Squibb CN 138-010
A randomized, double-blind, placebo-controlled study of aripiprazole in the maintenance treatment of patients with Bipolar Disorder.

2000 — Primary Investigator
Lilly F1D-US-HGHC
Prevalence of Hyperprolactinemia in Schizophrenic patients treated with anti-psychotic drugs.

2001 — Primary Investigator
Lilly F1D-US-HGHH
Olanzapine in the reduction of Hyperprolactinemia and associated morbidity in Schizophrenic patients.

1999-01 — Primary Investigator
Lilly F1D-MC-HGIP
Open-Label Combination of Olanzapine and Fluoxetine in Major Depressive Disorder.

1999-00 — Primary Investigator
Lilly F1D-MC-HGHZ
The combination of Olanzapine and Fluoxetine in Treatment Resistant Depression without Psychotic features

1999-00 — Primary Investigator
Pfizer 0501017
A multicenter 10-week randomized double-blind placebo controlled flexible dose outpatients study of Sertraline in children and adolescents with Major Depressive Disorder.

1999-00 — Primary Investigator
Forest SCT-MD-01
Fixed dose comparison of the safety and efficacy of Lu 26-054, Citalopram, and placebo in the treatment of Major Depressive Disorder.

1999-00 — Primary Investigator
Forest SCT-MD-03
Open-Label study of Lu26-054 in the treatment of Major Depressive Disorder.

1999-00 — Primary Investigator
Lilly F1D-MC-HGHX
A double-blind placebo-controlled comparison of the efficacy and safety of short-acting IM Olanzapine, short-acting IM Lorazepam, and IM placebo in treating agitation in patients with Dementia of the Alzheimer’s Type, Vascular Dementia, and Mixed Dementia.

1999-00 — Primary Investigator
Lilly F1D-US-HGHQ
Olanzapine versus Divalproex in the treatment of acute mania.

1998-99 — Primary Investigator
Roche WV15825
A double-blind, randomized, placebo-controlled study of Ro 64-0796 used in elderly subjects for the prevention of clinical influenza during the influenza season.

1998-99 — Primary Investigator
Abbott M97-696
A multi-center, double-blind, placebo-controlled study to evaluate the safety and efficacy of Depakote CR in the treatment of acute mania in bipolar disorder patients.

1998-99 — Primary Investigator
Abbott M97-738
A multi-center, double-blind, placebo-controlled study of Depakote in the treatment of signs and symptoms of mania in elderly patients with dementia.

1998-01 — Primary Investigator
Abbott M98-817
A multi-center, open-label study of Depakote in the treatment of signs and symptoms of mania in elderly patients with dementia.

1997-98— Primary Investigator
Zeneca 5077US/0004
A multi-center randomized comparison of Seroquel and Risperdal, to assess efficacy, safety, and tolerability in treatment of psychotic disorders.

1993-94— Primary Investigator
Bristol-Myers Squibb
A multi-center open label study to evaluate efficacy of Serzone in treatment of major depression.

1992-93— Co-Investigator
Mental Status Changes with Steroid Prophylaxis in Cardiac Angiography
Veterans Administration Hospital
Department of Psychiatry and Radiology
University of California, San Diego

1992-93 — Primary Investigator
Withdrawal of Neuroleptics in Geriatric Patients
Veterans Administration Hospital
Department of Psychiatry, Geropsychiatry Division
University of California, San Diego
Developed research protocol for 5-year study to evaluate cognitive deficits associated with neuroleptics, course of relapse off medication, medication withdrawal symptoms, and withdrawal emergent dyskinesias in geriatric patients.

PRESENTATIONS

Management of the Aggressive Patient in an Urgent Care Medical Facility
Grand Rounds, Kaiser Permanente Department of Urgent Care
Walnut Creek, CA
May, 1994

Eating Disorders
UC Davis School of Medicine
March, 1995 and February, 1996

Pharmacologic Issues in Psychiatry
UC Davis School of Medicine
August, 1995

Pharmacologic and Case Management of a Complicated Dementia Patient
Interdisciplinary Grand Rounds - Department of Mental Health
David Grant Medical Center, Travis Air Force Base
September, 1995

Nefazadone: Has It Fulfilled It's Promise?
San Francisco, CA
March, 1996

New Treatments for Depressed and Anxious Patients
San Francisco, CA
August, 1996

Depressed Patients with Symptoms of Anxiety
Grand Rounds - Veteran's Administration
Oakland Mental Health Clinic
September, 1996

A Clinician’s Perspective: The Ins and Outs of Seroquel
Zeneca District Emphasis Meeting
Reno, Nevada
May, 1998

Focus on Quetiapine
Oakland, CA
May, 1998

Clinical Impressions of Seroquel: The First Year
Roundtable Discussion
San Francisco, CA
June, 1998

Update on Seroquel
San Mateo County Psychiatric Association
San Mateo, CA
June, 1998

Use of Quetiapine in Clinical Practice
Kaiser Permanente

• Sacramento, CA            June, 1998
• Walnut Creek, CA            July, 1998
• Oakland, CA            July, 1998
• Santa Rosa, CA            August, 1998
• Hayward, CA            September, 1998
• Santa Clara, CA            October, 1998
• San Diego, CA            December, 1998

Update on Atypical Antipsychotics
Psychiatry Research Unit
San Francisco General Hospital
San Francisco, CA
September, 1998

Practical Issues in the Clinical Use of the Newest Antipsychotic Agents
McCauley Psychiatric Institute
St. Mary's Hospital
San Francisco, CA
September, 1998

New Uses for Atypical Antipsychotic Agents
Program Directors' Meeting
Heritage Oaks Hospital
Sacramento, CA
October, 1998

Updated Issues on Diagnosis and Management of Depression
Parke-Davis & Forest Pharmaceuticals, Inc.
Santa Rosa, CA
October, 1998

Review of Atypical Antipsychotics: Focus on Quetiapine
San Mateo, CA
November, 1998

Atypical Antipsychotics in Clinical Practice
San Jose, CA
January, 1999

Clinical Uses and Case Studies with Atypical Antipsychotics
Southern California Psychiatric Association
San Bernadino, CA
January, 1999

An Update on the Use of Atypical Antipsychotics
Inland Region-California Psychiatric Association
San Bernadino, CA
January, 1999

Quetiapine: Dosing Strategies and Case Studies
Zeneca District Emphasis Meeting
Las Vegas, Nevada
February, 1999

Atypical Antipsychotics in Acute Psychiatric Patients
Grand Rounds, Nevada State Hospital
Reno, Nevada
February, 1999

Use of Atypical Antipsychotics in Adult and Geriatric Patients
Grand Rounds, Summit Senior Bridges Hospital
Oakland, CA
February, 1999

Update on Antipsychotics: A Review of the QUEST Trial
Grand Rounds, Dept. of Psychiatry
UC Irvine, Medical Center
March, 1999

Atypical Antipsychotics: Clinical Uses and Dosing Strategies
Brea, CA
March, 1999

Update on Atypical Antipsychotics: Focus on Seroquel
Eureka, CA
March, 1999

Clinical Perspectives on Atypical Antipsychotics
Community Mental Health Department
Ukiah, CA
March, 1999

Use of Atypical Antipsychotics in the Geriatric Population
Grand Rounds, Laguna Honda Hospital
San Francisco, CA
March, 1999

Valley Area Physician Talk
Santa Barbara & Burbank
June, 1999

Roundtable Dinner Program on Psychosis
Phoenix, AZ
August, 1999

Grand Rounds, Regional Office of Mental Health
New Orleans, LA
August, 1999

Atypical Antipsychotics with Focus on Quetiapine
Burbank, CA
September, 1999

Atypical Antipsychotics: Side Effect Profiles & Dosing Stratagies
Tucson, AZ
September, 1999

Dosing Strategies with Quetiapine
Seroquel National Speakers Update Meeting,
Phoenix, AZ
November, 1999

Grand Rounds
Yuba/Sutter Mental Health
Sacramento, CA
November, 1999

Comparing Atypical Antipsychotics
Managed Care Meeting
Yountville, CA
November, 1999

Atypical Antispychotics
Seattle, WA
March, 2000

Parkinson’s Disease and Psychosis
Kahului, HI
March, 2000

Side Effect Profiles and Dosing Strategies with Atypical Antipsychotics
Santa Barbara, CA
April, 2000

New Applications and Dosing Strategies with Atypical Antipsychotics
Vista Del Mar, CA
April, 2000

Review & Update of Atypical Antipsychotics
Family & Child Therapy Center
Racine, WI
August, 2000

Atypical Antipsychotics
Milwaukee, WI
August, 2000

A New Atypical Antipsychotic
Allina Behavioral Health Teleconference
Minneapolis, MN
September, 2000

Pharmacologic Profiles of Newer Antipsychotics
Grand Rounds, Veteran’s Administrative Hospital
Tucson, AZ
November, 2000

Update on Side Effects of Antipsychotic Therapy
Tucson, AZ
November, 2000

Seroquel Faculty Update Meeting
Chairperson, Moderator, Speaker
Sonoma, CA
December, 2000

Issues in the Management of Schizophrenia
Sonoma, CA
December, 2000

Side Effect Profiles with of Antipsychotic Therapy
Whitehall, WI
February, 2001

Update on Side Effects of Antipsychotic Therapy
Chinatown/Northbeach Mental Health Clinic
San Francisco, CA
March, 2001

Update on Side Effects of Antipsychotic Therapy
Citywide Community Focus Center
San Francisco, CA
April, 2001

Pharmacologic Profiles of Newer Antipsychotics
San Mateo, CA
April, 2001

Issues in the Management of Schizophrenia
Santa Rosa, CA
October, 2001

Case Studies of Psychosis
San Francisco, CA
November, 2001

Antisychotic Use in Special Populations
Grand Rounds, San Joaquin County Mental Health
Stockton, CA
April, 2002

Issues in the Management of Schizophrenia
Chinatown Mental Health Clinic
San Francisco, CA
May, 2002

Psychiatric Case Study Program
San Francisco, CA
May, 2002

Antipsychotic Use in Special Populations
Grand Rounds, Dominican Hospital
Santa Cruz, CA
July, 2002

The”Ups” and “Downs” of the Newer Atypical Antipsychotic Medications
Redwood City, CA
July, 2002

Using Medical Consequences of Atypical Antipsychotics to Guide Choices in Special Populations
Grand Rounds, Alameda County Mental Health
Oakland, CA
October, 2002

Are Therapeutic Targets in ADHD Keeping Pace With Advancements in Treatment?
Mediator
Seattle, WA
December, 2002

Recognition, Diagnosis, and Treatment of Adult ADHD: Clinical Perspectives
Strattera Speaker Bureau Summit
Santa Ana Pueblo, NM
March 2003

Clinical Perspectives on a New Treatment Option for ADHD
Walnut Creek, CA
March 2003

ADHD in Women: Evedence, Diagnosis, and Treatment
Kaiser-Permanente Northern California Region Annual Conference for Psychiatry and Chemical Dependency Clinicians.
San Francisco, CA
April 2003

Case Study in the Management of Schizophrenia
Lafayette, CA
May 2003

ADHD in Adults:  The Often Missed Diagnosis “Introducing a New Diagnostic Tool for Primary Care Physicians.”
NAAAC (National Alliance for the Advancement of ADHD Care) Saturday Seminars
Houston, TX
June 2003

Antipsychotic Use in Special Populations
Eden Community Support
San Leandro, CA
January 2004

Adult ADHD
Danville, Berkeley, Lafayette, CA
March 2004

Clinical Insights: Antipsychotic Therapy for Bipolar Mania
Lafayette, CA
April 2004